CA2651934A1 - Dosage de marqueur biologique par spectrometrie de masse - Google Patents
Dosage de marqueur biologique par spectrometrie de masse Download PDFInfo
- Publication number
- CA2651934A1 CA2651934A1 CA002651934A CA2651934A CA2651934A1 CA 2651934 A1 CA2651934 A1 CA 2651934A1 CA 002651934 A CA002651934 A CA 002651934A CA 2651934 A CA2651934 A CA 2651934A CA 2651934 A1 CA2651934 A1 CA 2651934A1
- Authority
- CA
- Canada
- Prior art keywords
- biomarker
- sample
- signal
- mass
- control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 118
- 238000004949 mass spectrometry Methods 0.000 title description 58
- 238000003556 assay Methods 0.000 title description 17
- 238000000034 method Methods 0.000 claims abstract description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 238000001228 spectrum Methods 0.000 claims abstract description 44
- 238000004458 analytical method Methods 0.000 claims abstract description 29
- 238000011524 similarity measure Methods 0.000 claims abstract description 11
- 230000014759 maintenance of location Effects 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 15
- 238000000132 electrospray ionisation Methods 0.000 claims description 14
- 238000004364 calculation method Methods 0.000 claims description 9
- 230000003595 spectral effect Effects 0.000 claims description 9
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 8
- 238000004401 flow injection analysis Methods 0.000 claims description 6
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 66
- 150000002500 ions Chemical class 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 24
- 238000004885 tandem mass spectrometry Methods 0.000 description 24
- 239000013598 vector Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000004811 liquid chromatography Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000012620 biological material Substances 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000013610 patient sample Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005040 ion trap Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000007837 multiplex assay Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 238000010847 SEQUEST Methods 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000091 biomarker candidate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004012 multidimensional HPLC Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- FYLHBMBOIMQLJO-UHFFFAOYSA-N 2-methylseleninyl-n-phenylbenzamide Chemical compound C[Se](=O)C1=CC=CC=C1C(=O)NC1=CC=CC=C1 FYLHBMBOIMQLJO-UHFFFAOYSA-N 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0611669.3A GB0611669D0 (en) | 2006-06-13 | 2006-06-13 | Mass spectrometry biomarker assay |
| GB0611669.3 | 2006-06-13 | ||
| PCT/GB2007/002187 WO2007144606A2 (fr) | 2006-06-13 | 2007-06-13 | dosage de marqueur biologique par spectrométrie de masse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2651934A1 true CA2651934A1 (fr) | 2007-12-21 |
Family
ID=36745797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002651934A Abandoned CA2651934A1 (fr) | 2006-06-13 | 2007-06-13 | Dosage de marqueur biologique par spectrometrie de masse |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2035829A2 (fr) |
| JP (1) | JP2009540319A (fr) |
| KR (1) | KR20090068199A (fr) |
| CN (1) | CN101611313A (fr) |
| AU (1) | AU2007258970A1 (fr) |
| BR (1) | BRPI0711967A2 (fr) |
| CA (1) | CA2651934A1 (fr) |
| GB (1) | GB0611669D0 (fr) |
| MX (1) | MX2008015158A (fr) |
| WO (1) | WO2007144606A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138069A (zh) * | 2008-07-23 | 2011-07-27 | P设备有限公司 | 便携式基于等离子体的诊断设备和诊断方法 |
| GB0906698D0 (en) | 2009-04-17 | 2009-06-03 | Queen Mary & Westfield College | Method for quantifying modified peptides |
| KR101144237B1 (ko) * | 2009-12-29 | 2012-05-11 | 한국기초과학지원연구원 | 고분해능 질량분석법과 약리활성검사를 이용한 천연물의 약리 활성물질 발굴 방법 |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| CN102201039A (zh) * | 2010-08-19 | 2011-09-28 | 上海聚类生物科技有限公司 | 一种分析ltq数据的方法 |
| GB201204278D0 (en) | 2012-03-09 | 2012-04-25 | Queen Mary & Westfield College | Method |
| FR3016461B1 (fr) * | 2014-01-10 | 2017-06-23 | Imabiotech | Procede de traitement de donnees d'imagerie moleculaire et serveur de donnees correspondant |
| DE102014000646B4 (de) * | 2014-01-17 | 2023-05-11 | Bruker Daltonics GmbH & Co. KG | Massenspektrometrische Resistenzbestimmung durch Metabolismus-Messung |
| GB201509313D0 (en) * | 2015-05-29 | 2015-07-15 | Micromass Ltd | Sample mass spectrum analysis |
| US11435354B2 (en) * | 2016-02-19 | 2022-09-06 | University Of Miyazaki | Adenocarcinoma detection method |
| CN109416360A (zh) * | 2016-03-31 | 2019-03-01 | 迪森德克斯公司 | 生物标志物数据库的生成和用途 |
| RU2756447C2 (ru) | 2016-05-24 | 2021-09-30 | Ин Ово Холдинг Б.В. | Способ и система для неразрушающего in ovo определения пола птицы |
| WO2018033894A1 (fr) * | 2016-08-19 | 2018-02-22 | Monash University | Systèmes et procédés spectroscopiques d'identification et de quantification d'agents pathogènes |
| US9905405B1 (en) * | 2017-02-13 | 2018-02-27 | Thermo Finnigan Llc | Method of generating an inclusion list for targeted mass spectrometric analysis |
| JP7194128B2 (ja) * | 2017-06-29 | 2022-12-21 | イェンタイ クワンティシジョン ディアグノスティックス インク | 固形腫瘍の診断用のバイオマーカーの絶対定量の方法および装置 |
| US10837970B2 (en) | 2017-09-01 | 2020-11-17 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
| US20210063410A1 (en) * | 2017-09-05 | 2021-03-04 | Discerndx, Inc. | Automated sample workflow gating and data analysis |
| GB2569805B (en) * | 2017-12-22 | 2023-03-08 | Asymptote Ltd | Method and system relating to cooling conditions for a biological sample |
| WO2019219651A1 (fr) * | 2018-05-15 | 2019-11-21 | Ventana Medical Systems, Inc. | Quantification de signaux dans des agrégats colorés |
| WO2020106218A1 (fr) * | 2018-11-23 | 2020-05-28 | Agency For Science, Technology And Research | Procédé d'identification d'un échantillon biologique inconnu à partir de multiples attributs |
| CN111672658B (zh) * | 2020-06-08 | 2022-05-13 | 惠州市新泓威科技有限公司 | 电子雾化设备最佳雾化温度的检测与控制方法及其电子雾化设备 |
| EP4047371A1 (fr) * | 2021-02-18 | 2022-08-24 | Thermo Fisher Scientific (Bremen) GmbH | Procédé et appareil pour analyser des échantillons de biomolécules à l'aide de la spectrométrie de masse avec acquisition indépendante des données |
| KR102632163B1 (ko) | 2022-04-13 | 2024-02-01 | 오보젠 주식회사 | 가금류 알(卵)의 암수 검사 및 선별장치 그리고 이를 이용한 선별방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1573044A4 (fr) * | 2002-12-18 | 2006-07-05 | Ciphergen Biosystems Inc | Biomarqueurs seriques du cancer du poumon |
| DE10324149A1 (de) * | 2003-05-26 | 2004-12-16 | Imat-Uve Gmbh | Verfahren und Vorrichtung zur GC/MS- oder LC/MS-Screeninganalyse |
| WO2005098445A2 (fr) * | 2004-03-30 | 2005-10-20 | Eastern Virginia Medical School | Biomarqueurs de cancer du poumon |
| US7851742B2 (en) * | 2004-05-20 | 2010-12-14 | Waters Technologies Corporation | Method and apparatus for identifying proteins in mixtures |
-
2006
- 2006-06-13 GB GBGB0611669.3A patent/GB0611669D0/en not_active Ceased
-
2007
- 2007-06-13 CA CA002651934A patent/CA2651934A1/fr not_active Abandoned
- 2007-06-13 CN CNA2007800219002A patent/CN101611313A/zh active Pending
- 2007-06-13 AU AU2007258970A patent/AU2007258970A1/en not_active Abandoned
- 2007-06-13 BR BRPI0711967-4A patent/BRPI0711967A2/pt not_active IP Right Cessation
- 2007-06-13 MX MX2008015158A patent/MX2008015158A/es not_active Application Discontinuation
- 2007-06-13 JP JP2009514893A patent/JP2009540319A/ja active Pending
- 2007-06-13 WO PCT/GB2007/002187 patent/WO2007144606A2/fr active Application Filing
- 2007-06-13 EP EP07733193A patent/EP2035829A2/fr not_active Withdrawn
- 2007-06-13 KR KR1020097000596A patent/KR20090068199A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB0611669D0 (en) | 2006-07-19 |
| AU2007258970A1 (en) | 2007-12-21 |
| KR20090068199A (ko) | 2009-06-25 |
| JP2009540319A (ja) | 2009-11-19 |
| CN101611313A (zh) | 2009-12-23 |
| MX2008015158A (es) | 2009-04-30 |
| WO2007144606A3 (fr) | 2008-04-03 |
| WO2007144606A2 (fr) | 2007-12-21 |
| BRPI0711967A2 (pt) | 2012-01-24 |
| EP2035829A2 (fr) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2651934A1 (fr) | Dosage de marqueur biologique par spectrometrie de masse | |
| Angel et al. | Mass spectrometry-based proteomics: existing capabilities and future directions | |
| Guerrera et al. | Application of mass spectrometry in proteomics | |
| US7538321B2 (en) | Method of identifying substances using mass spectrometry | |
| JP4932834B2 (ja) | 保持時間整合を行うための方法および装置 | |
| EP2279260B1 (fr) | Techniques pour effectuer une correspondance rétention-temps d'ions précurseurs et produits et pour construire des spectres d'ions précurseurs et produits | |
| US20100233815A1 (en) | Methods for the Development of a Biomolecule Assay | |
| EP1446667A2 (fr) | Systeme de profilage de l'intensite de masse et utilisations correspondantes | |
| WO2006133109A1 (fr) | Methodes et appareil pour analyses chimiques basees sur le fractionnement | |
| US7070949B2 (en) | Protein mixture analysis by mass spectrometry | |
| Fuller et al. | Quantitative proteomics using iTRAQ labeling and mass spectrometry | |
| Zhao et al. | Evolution of mass spectrometry instruments and techniques for blood proteomics | |
| EP1887351A1 (fr) | Procede de criblage pour une proteine specifique dans une analyse detaillee du proteome | |
| Masselon et al. | Identification of tryptic peptides from large databases using multiplexed tandem mass spectrometry: simulations and experimental results | |
| Merkley et al. | A proteomics tutorial | |
| Hall et al. | Isotope-differentiated binding energy shift tags (IDBEST™) for improved targeted biomarker discovery and validation | |
| WO2005057208A1 (fr) | Procede d'identification de peptides et de proteines | |
| Vaezzadeh et al. | Proteomics and opportunities for clinical translation in urological disease | |
| Meyers et al. | Protein identification and profiling with mass spectrometry | |
| ÜNAL | Mass Spectrometry in Clinical Diagnosis: Cancer Biomarkers | |
| Hathout et al. | Current Proteome Profiling Methods | |
| JPWO2007072648A1 (ja) | 質量分析システムおよび質量分析方法 | |
| Nicolardi | Development of ultrahigh resolution FTICR mass spectrometry methods for clinical proteomics | |
| Borchers et al. | CH 12 Application of Proteomics in Basic Biological Sciences and Cancer | |
| Conrads et al. | Mass Spectrometry‐Based Proteomic Approaches for Disease Diagnosis and Biomarker Discovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |